ストックスクリーナーアプリを入手
6.00
3.63%
0.21
プレマーケット:
6.29
0.29
+4.83%
前日終値:
$5.79
開ける：
$5.87
24時間の取引高:
376.72K
Relative Volume:
1.70
時価総額：
$270.35M
収益：
-
当期純損益:
$-32.74M
株価収益率:
-7.3171
EPS:
-0.82
ネットキャッシュフロー:
$-24.89M
1週間 パフォーマンス:
+0.17%
1か月 パフォーマンス:
-44.65%
6か月 パフォーマンス:
-49.20%
1年 パフォーマンス:
-38.21%
1日の値動き範囲:
$5.82
$6.38
1週間の範囲:
$5.5977
$6.38
52週間の値動き範囲:
$5.5977
$16.94
Third Harmonic Bio Inc Stock (THRD) Company Profile
名前
Third Harmonic Bio Inc
セクター
電話
(209) 727-2457
住所
1700 MONTGOMERY STREET, SAN FRANCISCO
THRD を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
THRD
Third Harmonic Bio Inc
|
6.00 | 270.35M | 0 | -32.74M | -24.89M | -0.82 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Third Harmonic Bio Inc Stock (THRD) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-08-09 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2024-06-18 | 開始されました | Stifel | Buy |
| 2024-06-07 | 開始されました | Raymond James | Outperform |
| 2022-12-16 | ダウングレード | Jefferies | Buy → Hold |
| 2022-12-15 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2022-10-10 | 開始されました | Cowen | Outperform |
| 2022-10-10 | 開始されました | Jefferies | Buy |
| 2022-10-10 | 開始されました | Morgan Stanley | Overweight |
すべてを表示
Third Harmonic Bio Inc (THRD) 最新ニュース
Trend Tracker for (THRD) - Stock Traders Daily
Jefferies cuts Third Harmonic stock target to $7 from $15 By Investing.com - Investing.com Canada
Third Harmonic Bio shares drop to lowest since 2023 By Investing.com - Investing.com Canada
Third Harmonic Bio stock hits 52-week low at $8.04 - Investing.com India
Dermata Therapeutics Inc (DRMA): Major Improvements, Worth A Look - Stocks Register
Stifel maintains positive outlook on Celldex and Third Harmonic stocks By Investing.com - Investing.com Canada
Revance gains as it plans to enter talks with Teoxane on likely superior bid (RVNC:NASDAQ) - Seeking Alpha
Learn to Evaluate (THRD) using the Charts - Stock Traders Daily
Pre-market Movers: CDT, NARI, GDTC, NARI... - RTTNews
Revance Therapeutics jumps after Teoxane offers $3.60 a share (NASDAQ:RVNC) - Seeking Alpha
Eton acquires Wilson disease drug Galzin (ETON:NASDAQ) - Seeking Alpha
Neumora stock drops on depression trial failure (NMRA:NASDAQ) - Seeking Alpha
Trading (THRD) With Integrated Risk Controls - Stock Traders Daily
Aquestive receives FDA Orphan Drug Exclusivity for Libervant - Seeking Alpha
Long Term Trading Analysis for (THRD) - Stock Traders Daily
Third Harmonic Bio's SWOT analysis: oral KIT inhibitor stock shows promise - Investing.com Australia
Third Harmonic Bio's SWOT analysis: stock outlook brightens on clinical progress - Investing.com India
Stock Market Analysis & Tools for Investors - Seeking Alpha
Third Harmonic Bio's SWOT analysis: stock outlook brightens on clinical progress By Investing.com - Investing.com South Africa
Revance Therapeutics plunges after Crown Labs cuts takeover price in half - Seeking Alpha
Atlas Venture Announces $450 Million Fund XIV - Yahoo Finance
How the (THRD) price action is used to our Advantage - Stock Traders Daily
Third Harmonic Bio to Participate in the 7th Annual Evercore HealthCONx Conference - Marketscreener.com
Third Harmonic Bio to Present at Evercore HealthCONx Conference in December | THRD Stock News - StockTitan
Wall Street Analysts Believe Third Harmonic Bio, Inc. (THRD) Could Rally 26.67%: Here's is How to Trade - MSN
Aclaris stock soars for second day on licensing deal, analyst upgrades (NASDAQ:ACRS) - Seeking Alpha
(THRD) Technical Pivots with Risk Controls - Stock Traders Daily
RA Capital Management Reduces Stake in Third Harmonic Bio Inc - GuruFocus.com
Significant Stake Increase by T. Rowe Price in Third Harmonic Bi - GuruFocus.com
Revance Therapeutics jumps after Crown Laboratories tender offer extended again - Seeking Alpha
Vertiv Rises 13% in a Month: Time for Investors to Buy the Stock? - MSN
Shiba Inu (SHIB) Price Rises 53% but Hits Rejection at Key Ascending Resistance Level - MSN
Canopy Growth stock on watch after Q2 results (CGC:NASDAQ) - Seeking Alpha
Third Harmonic Bio Reports Q3 2024 Financial Results - TipRanks
Third Harmonic Bio Inc (THRD) Quarterly 10-Q Report - Quartzy
Third Harmonic Bio (THRD) to Present at Major Stifel, Jefferies Healthcare Conferences | THRD Stock News - StockTitan
Marquis Who's Who Honors Jonathan Colon, PhD, for Expertise in Biotechnology - 24-7 Press Release
Third Harmonic Flat on Q3 Results - Baystreet.ca
Third Harmonic Bio Announces Third Quarter 2024 Financial Results - The Manila Times
Third Harmonic Bio Reports $296M Cash Position, Phase 1 Trial Progress Despite Wider Q3 Loss | THRD Stock News - StockTitan
An RNAi renaissance is creating a new generation of startups - BioPharma Dive
(THRD) Technical Data - Stock Traders Daily
Third harmonic bio sees $14.3 million in stock sales by BVF Partners - Investing.com India
Jade, another biotech spinout of Paragon, to merge with Aerovate - BioPharma Dive
Third Harmonic Bio's chief medical officer sells $40,095 in stock - Investing.com
A new biotech, built around protein design, springs from David Baker’s lab - BioPharma Dive
Harmonic Third Quarter 2024 Earnings: Beats Expectations - Yahoo Finance
Down -18.64% in 4 Weeks, Here's Why Philips (PHG) Looks Ripe for a Turnaround - MSN
Revance Therapeutics surges after Crown tender offer extended, settles with Teoxane - Seeking Alpha
Where are the Opportunities in (THRD) - Stock Traders Daily
Harmonic Discovery presents FLT3 kinase inhibitor with enhanced safety profile - BioWorld Online
Third Harmonic Bio Inc (THRD) 財務データ
収益
当期純利益
現金流量
EPS
4.81%
大文字化:
|
ボリューム (24 時間):